- Home
- REXR vs LEGN Comparison
REXR vs LEGN Comparison
Compare REXR & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REXR
- LEGN
- Stock Information
- Founded
- REXR 2013
- LEGN 2014
- Country
- REXR United States
- LEGN United States
- Employees
- REXR N/A
- LEGN N/A
- Industry
- REXR Real Estate Investment Trusts
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- REXR Real Estate
- LEGN Health Care
- Exchange
- REXR Nasdaq
- LEGN Nasdaq
- Market Cap
- REXR 7.7B
- LEGN 7.0B
- IPO Year
- REXR 2013
- LEGN 2020
- Fundamental
- Price
- REXR $35.71
- LEGN $27.78
- Analyst Decision
- REXR Hold
- LEGN Strong Buy
- Analyst Count
- REXR 9
- LEGN 13
- Target Price
- REXR $42.11
- LEGN $75.67
- AVG Volume (30 Days)
- REXR 2.3M
- LEGN 1.5M
- Earning Date
- REXR 04-16-2025
- LEGN 05-13-2025
- Dividend Yield
- REXR 4.81%
- LEGN N/A
- EPS Growth
- REXR 12.67
- LEGN N/A
- EPS
- REXR 1.23
- LEGN N/A
- Revenue
- REXR $974,598,000.00
- LEGN $728,303,000.00
- Revenue This Year
- REXR $9.99
- LEGN $65.96
- Revenue Next Year
- REXR $8.93
- LEGN $52.55
- P/E Ratio
- REXR $29.07
- LEGN N/A
- Revenue Growth
- REXR 18.04
- LEGN 112.46
- 52 Week Low
- REXR $29.68
- LEGN $29.27
- 52 Week High
- REXR $52.61
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- REXR 57.07
- LEGN 29.61
- Support Level
- REXR $34.78
- LEGN $30.25
- Resistance Level
- REXR $36.55
- LEGN $33.30
- Average True Range (ATR)
- REXR 0.74
- LEGN 1.78
- MACD
- REXR 0.42
- LEGN -0.57
- Stochastic Oscillator
- REXR 80.33
- LEGN 5.19
About REXR Rexford Industrial Realty Inc.
Rexford Industrial Realty Inc is a real estate investment trust engaged in owning, operating, and acquiring industrial properties in Southern California infill markets. The goal is to generate attractive risk-adjusted returns for stockholders by providing superior access to industrial property investments in Southern California infill markets. It has one operating segment business of investing in, operating, and repositioning/redeveloping industrial real estate properties located in Southern California infill markets.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.